The official journal of the Brazilian Retina and Vitreous Society
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effecti...